Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-02-12

FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) from Janssen Biotech, Inc., to update the product labeling. Thi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))

Snippet

SUPPL AP for DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT))